News/ News/ R&D Another NASH setback as CymaBay drops seladelpar Phil Taylor CymaBay Therapeutics, hepatology, NASH 0 Comment CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), Share X Another NASH setback as CymaBay drops seladelpar https://pharmaphorum.com/news/another-nash-setback-as-cymabay-drops-seladelpar/
